BCL2 and B-cell non-Hodgkin lymphoma: On the other hand, treatment of high-risk DLBCL with ABT-199 combined with the potent new cyclin-dependent kinase inhibitor dinaciclib [383], which knocks down MCL1 by inhibiting CDK9 [379, 383], synergistically induced tumor regression, in xenografts and in a genetically accurate murine model of c-MYC/BCL2 double-hit B-cell lymphoma [379].